Literature DB >> 35013934

Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease.

Kenneth M Heilman1,2,3, Stephen E Nadeau4,5,6.   

Abstract

Alzheimer's disease is associated with impairments in emotional communication including comprehension and production of facial emotional expressions, comprehension of affective prosody, and alexithymia. It is also associated with disorders of emotional experience including mood disorders (depression and anxiety), agitation/aggression, and psychosis. Agitation/aggression and psychosis are particularly disruptive, are associated with earlier institutionalization, and pose a major challenge to institutional management. Treatment of disorders of emotional experience has been primarily pharmacologic (reviewed here in detail) and has relied heavily on antipsychotic medications despite the small effect sizes demonstrated in a large number of randomized controlled trials and the prevalence of serious side effects associated with these drugs. Recent studies suggest that treatment with pimavanserin, an antipsychotic without activity at dopamine receptors, may represent an important advance for treatment of psychotic manifestations, even as the drug appears to pose significant risk. Dextromethorphan/quinidine may represent an important advance in the treatment of agitation/aggression. There is also compelling evidence that sleep disorders, which are common among patients with Alzheimer's disease and are readily treatable, may potentiate psychotic manifestations and agitation/aggression, but further studies are needed.
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  Agitation/aggression; Alexithymia; Alzheimer’s disease; Depression; Emotional facial expression; Emotional prosody; Psychosis; Sleep disorders

Mesh:

Substances:

Year:  2022        PMID: 35013934      PMCID: PMC9130428          DOI: 10.1007/s13311-021-01172-w

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   6.088


  154 in total

1.  Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.

Authors:  George T Grossberg; Eva Kohegyi; Victor Mergel; Mette Krog Josiassen; Didier Meulien; Mary Hobart; Mary Slomkowski; Ross A Baker; Robert D McQuade; Jeffrey L Cummings
Journal:  Am J Geriatr Psychiatry       Date:  2019-10-01       Impact factor: 4.105

2.  Early Emotional Attention is Impacted in Alzheimer's Disease: An Eye-Tracking Study.

Authors:  Jessica Bourgin; Nathalie Guyader; Alan Chauvin; Alexandra Juphard; Mathilde Sauvée; Olivier Moreaud; Laetitia Silvert; Pascal Hot
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.

Authors:  C Holmes; D Wilkinson; C Dean; S Vethanayagam; S Olivieri; A Langley; N D Pandita-Gunawardena; F Hogg; C Clare; J Damms
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

4.  Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.

Authors:  Raffaele Rea; Anna Carotenuto; Enea Traini; Angiola Maria Fasanaro; Valentino Manzo; Francesco Amenta
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

5.  Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.

Authors:  Peter Paul De Deyn; Manuel Martín Carrasco; Walter Deberdt; Claude Jeandel; Donald P Hay; Peter D Feldman; Carrie A Young; Deborah L Lehman; Alan Breier
Journal:  Int J Geriatr Psychiatry       Date:  2004-02       Impact factor: 3.485

Review 6.  Depression in Alzheimer's disease: epidemiology, mechanisms, and management.

Authors:  Song Chi; Jin-Tai Yu; Meng-Shan Tan; Lan Tan
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

7.  A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.

Authors:  Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Clarnette; Emma Lee; Ben Lyons; Fred Grossman
Journal:  J Clin Psychiatry       Date:  2003-02       Impact factor: 4.384

8.  A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia.

Authors:  Horia Paunescu; Lorena Dima; Isabel Ghita; Laurenţiu Coman; Petru Iulian Ifteni; Ion Fulga; Oana Andreia Coman
Journal:  Am J Ther       Date:  2020 May/Jun       Impact factor: 2.688

9.  Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.

Authors:  Noll Campbell; Amir Ayub; Malaz A Boustani; Chris Fox; Martin Farlow; Ian Maidment; Robert Howards
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

View more
  4 in total

1.  The Broad Range of Research in Alzheimer's Disease and Related Dementias.

Authors:  Steven T DeKosky; Ranjan Duara
Journal:  Neurotherapeutics       Date:  2022-05-13       Impact factor: 6.088

Review 2.  Primary Palliative Care in Dementia.

Authors:  Neal Weisbrod
Journal:  Neurotherapeutics       Date:  2022-01-26       Impact factor: 6.088

3.  Neuroprotective Effects of Phytochemicals against Aluminum Chloride-Induced Alzheimer's Disease through ApoE4/LRP1, Wnt3/β-Catenin/GSK3β, and TLR4/NLRP3 Pathways with Physical and Mental Activities in a Rat Model.

Authors:  Ahmed Mohsen Elsaid Hamdan; Fatimah Hussain J Alharthi; Ahmed Hadi Alanazi; Soad Z El-Emam; Sameh S Zaghlool; Kamel Metwally; Sana Abdulaziz Albalawi; Yahia S Abdu; Reda El-Sayed Mansour; Hoda A Salem; Zakaria Y Abd Elmageed; Karema Abu-Elfotuh
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-17

4.  Rosmarinus officinalis and Methylphenidate Exposure Improves Cognition and Depression and Regulates Anxiety-Like Behavior in AlCl3-Induced Mouse Model of Alzheimer's Disease.

Authors:  Nishat Malik; Sanila Amber; Saadia Zahid
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.